Source: Fortune
Summary
The FDA is introducing a pilot program to pay employees cash bonuses for completing drug reviews ahead of schedule. The program, called “Reviewer Recognition and Excellence,” aims to address growing bottlenecks in the pharmaceutical approval process while maintaining scientific standards. The agency has lost 20% of its employees since President Donald Trump began his second term, and the bonuses may also serve as an incentive for employees to stay. The program will reward review staff for efficiency and excellence, but will not change review criteria or quality safeguards.
Our Reading
The strategy enters a familiar phase.
FDA Commissioner Marty Makary is using a private-sector tactic to boost productivity. The agency is trying to address a surge in new drug applications, driven by health-focused companies and venture capital. The FDA has a program in place to expedite reviews, but this is the first time it’s directly paying staffers for meeting timelines. The bonuses are intended to recognize and reward staff for efficiency and high-quality work.
The FDA is also experimenting with generative AI to expedite the review process, but experts raise concerns about trading public health for better stats.
One thing is clear: the FDA is trying to speed up the approval process, and it’s willing to try new things to get there.
Author: Evan Null
